Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Lilly’s neutralizing antibody shows promise in COVID-19

by Lisa M. Jarvis
September 19, 2020 | A version of this story appeared in Volume 98, Issue 36

 

Eli Lilly and Company has unveiled early data from a Phase II clinical trial of LY-CoV555, a neutralizing antibody designed to prevent the novel coronavirus from entering human cells. In the study, people with mild to moderate symptoms of COVID-19 took one of three doses of the drug or a placebo. People given the middle dose cleared the virus significantly faster than those given a placebo, Lilly says. And overall, only 1.7% of people given any dose were hospitalized, compared with 6.0% given the placebo.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.